Small Molecule Drug Discovery Through AstraZeneca High-Throughput Screening

This Medical Research Council (MRC) funded opportunity enables academic researchers to accelerate early-stage drug discovery by accessing AstraZeneca's extensive resources. Researchers gain access to a compound library containing over two million molecules and state-of-the-art high-throughput screening equipment at AstraZeneca facilities. This program supports up to four projects annually and is designed to identify promising starting points for small molecule medicinal drug development. The collaboration leverages AstraZeneca's screening infrastructure and chemical expertise to help academic teams move from initial hypothesis to validated lead compounds, reducing the time and cost of early-stage pharmaceutical research.